Amedisys (Amedisys) Debt-to-Equity

: 0.46 (As of Dec. 2023)

View and export this data going back to 1994. Start your Free Trial

Amedisys's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $63 Mil. Amedisys's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $425 Mil. Amedisys's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $1,067 Mil. Amedisys's debt to equity for the quarter that ended in Dec. 2023 was 0.46.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Amedisys's Debt-to-Equity or its related term are showing as below:

AMED' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.34 Max: 0.59
Current: 0.46

During the past 13 years, the highest Debt-to-Equity Ratio of Amedisys was 0.59. The lowest was 0.02. And the median was 0.34.

AMED's Debt-to-Equity is ranked better than
50.46% of 545 companies
in the Healthcare Providers & Services industry
Industry Median: 0.47 vs AMED: 0.46

Amedisys Debt-to-Equity Historical Data

The historical data trend for Amedisys's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amedisys Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.51

0.38

0.59

0.51

0.46

Amedisys Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																0.51	0.45	0.48	0.47	0.46

Competitive Comparison

For the Medical Care Facilities subindustry, Amedisys's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amedisys Debt-to-Equity Distribution

For the Healthcare Providers & Services industry and Healthcare sector, Amedisys's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Amedisys's Debt-to-Equity falls into.

Amedisys Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Amedisys's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(62.6	+	424.613)	/	1066.514
	=	0.46

Amedisys's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(62.6	+	424.613)	/	1066.514
	=	0.46

Amedisys (NAS:AMED) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Amedisys Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Amedisys's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Amedisys (Amedisys) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Amedisys Inc (NAS:AMED) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

ADY:Germany ADY:Germany

Address

3854 American Way, Suite A, Baton Rouge, LA, USA, 70816

Website

https://www.amedisys.com

Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, high acuity care segment, and personal care services. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States, Hospice segment operates many centers designed to provide comfort and support for terminally ill patients, Personal Care Segment provides individuals with assistance in their daily living activities and High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.

Executives

Allyson Guidroz	officer: Chief Accounting Officer	3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Richard M Ashworth	director, officer: President and CEO	200 WILMOT ROAD, DEERFIELD IL 60015
Michael Paul North	officer: Chief Information Officer	3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Adam Y Holton	officer: Chief People Officer	C/O CHS INC., 5500 CENEX DRIVE, INVER GROVE HEIGHTS MN 55077
Denise M. Bohnert	officer: Chief Compliance Officer	3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Nick Muscato	officer: Chief Strategy Officer	3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Richard A Lechleiter	director	PO BOX 32890, LOUISVILLE KY 40232-2890
Bruce D Perkins	director	500 WEST MAIN STREET, LOUISVILLE KY 40202
Christopher Gerard	officer: Chief Operating Officer	3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Vickie L Capps	director	2985 SCOTT STREET, VISTA CA 92083
Teresa L. Kline	director	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Jeffrey A Rideout	director	2142 DEER OAK WAY, DANVILLE CA 94506
Julie D Klapstein	director	1239 FRUIT COVE ROAD NORTH, JACKSONVILLE FL 32259
Molly Joel Coye	director	AETNA INC, 151 FARMINGTON AVENUE, HARTFORD CT 06156
David L Kemmerly	officer: See Remarks	3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816